MedTrace Logo

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

NCT04056975 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-08-14

No results posted yet for this study

Summary

Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Conditions

  • Relapsed or Refractory B-cell Lymphoma

Interventions

BIOLOGICAL

Recombinant Anti-CD19m-CD3 Antibody Injection

Intravenous Infusion

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • EVIVE Biotechnology

    lead INDUSTRY

Principal Investigators

  • Song Yuqin, Doctor · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-15
Primary Completion
2021-09-30
Completion
2022-01-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04056975 on ClinicalTrials.gov